NCT02304393View on ClinicalTrials.gov

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 12, 2014

Primary Completion Date

November 7, 2019

Study Completion Date

November 7, 2019

Conditions
Solid Tumors
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.

DRUG

Selicrelumab

Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.

Trial Locations (11)

2100

Rigshospitalet; Onkologisk Klinik, København Ø

13385

Aphm; Cpcet, Marseille

19104

University of Pennsylvania, Philadelphia

28050

START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid

75475

Hopital Saint Louis, Service D Oncologie Medicale, Paris

94805

Institut Gustave Roussy; Sitep, Villejuif

M5G 2M9

University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto

H3T 1E2

Jewish General Hospital / McGill University, Montreal

1066 CX

Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

3015 GD

Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed, Rotterdam

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02304393 - A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter